Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Oregon
mi
from
Oregon, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Oregon
mi
from
Oregon, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
North Coast Cancer Care
mi
from
Sandusky, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
North Coast Cancer Care
mi
from
Sandusky, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Flower Hospital
mi
from
Sylvania, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Children's Hospital
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Vincent Mercy Medical Center
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
University of Toledo
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
University of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Community Hospital Oncology Program CCOP
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Community Hospital Oncology Program CCOP
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Cancer Center at Saint Anne Mercy Hospital
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Cancer Center at Saint Anne Mercy Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Toledo Clinic Cancer Centers-Toledo
mi
from
Toledo, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Toledo Clinic Cancer Centers-Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Upper Valley Medical Center
mi
from
Troy, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Fulton County Health Center
mi
from
Wauseon, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Adventist Medical Center
mi
from
Portland, OR
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Adventist Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Center
mi
from
Danville, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Center-Cancer Center Hazelton
mi
from
Hazleton, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Center-Cancer Center Hazelton
mi
from
Hazleton, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Medical Group
mi
from
State College, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Medical Group
mi
from
State College, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Fredericksburg Oncology Inc
mi
from
Fredericksburg, VA
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Fredericksburg Oncology Inc
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Midelfort Clinic-Clairemont Campus
mi
from
Eau Claire, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Midelfort Clinic-Clairemont Campus
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Mayo Clinic Health System Eau Claire Hospital - Luther Campus
mi
from
Eau Claire, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Mayo Clinic Health System Eau Claire Hospital - Luther Campus
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Saint Mary's Hospital
mi
from
Green Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Bay Area Medical Center
mi
from
Marinette, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  7/31/2015
Welch Cancer Center
mi
from
Sheridan, WY
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 7/31/2015
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
A Pilot Study of Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
Status: Enrolling
Updated:  7/31/2015
Massachusetts General Hospital
mi
from
Boston, MA
Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
A Pilot Study of Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
Status: Enrolling
Updated: 7/31/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated:  8/3/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer
Status: Enrolling
Updated: 8/3/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Visions Clinical Research
mi
from
Tucson, AZ
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Visions Clinical Research
mi
from
Tucson, AZ
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Middlesex Hospital Cancer Center
mi
from
Middletown, CT
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Middlesex Hospital Cancer Center
mi
from
Middletown, CT
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Advance Medical Research Service Corp
mi
from
Miami, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Advance Medical Research Service Corp
mi
from
Miami, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Accord Clinical Research
mi
from
Port Orange, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Accord Clinical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Springfield Clinic
mi
from
Springfield, IL
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
New Orleans Research Institute
mi
from
Metairie, LA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
New Orleans Research Institute
mi
from
Metairie, LA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Commonwealth Clinical Trials
mi
from
Brockton, MA
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Commonwealth Clinical Trials
mi
from
Brockton, MA
Click here to add this to my saved trials
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated:  8/3/2015
Beaumont Hospital
mi
from
Royal Oak, MI
Head to Head Study Epi proColon and FIT
Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population
Status: Enrolling
Updated: 8/3/2015
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials